Author:
Chan David L.,Ferone Diego,Albertelli Manuela,Pavlakis Nick,Segelov Eva,Singh Simron
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference48 articles.
1. F.T. Bosman, World Health Organization, International Agency for Research on Cancer (ed.), in WHO Classification of Tumours of the Digestive System, 4th edn. (International Agency for Research on Cancer, Lyon, 2010)
2. A. Rinke, H.-H. Müller, C. Schade-Brittinger, K.-J. Klose, P. Barth, M. Wied et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J. Clin. Oncol. 27, 4656–4663 (2009)
3. M.E. Caplin, M. Pavel, J.B. Cwikla, A.T. Phan, M. Raderer, E. Sedlackova et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 371, 224–233 (2014)
4. E. Raymond, L. Dahan, J.L. Raoul, Y.J. Bang, I. Borbath, C. Lombard-Bohas et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011)
5. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, E. Van Cutsem et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011)